Open AccessIn vitro activity of WIN 49375 compared with those of other antibiotics in isolates from cancer patients
Author(s) -
I. Garcia,
Gerald P. Bodey,
Victor Fainstein,
Dah Hsi Ho,
Barbara LeBlanc
Publication year - 1984
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.26.3.421
Subject(s) - serratia marcescens , enterobacter cloacae , microbiology and biotechnology , klebsiella pneumoniae , pseudomonas aeruginosa , in vitro , antibiotics , enterobacteriaceae , biology , enterobacter , escherichia coli , quinolone , bacteria , biochemistry , genetics , gene
The activity of WIN 49375 [6-fluoro-1, 4-dihydro-1-(methylamino)-7-(4-methyl-1-piperazinyl)-4-oxo-3- quinolinecarboxylic acid], a new synthetic quinolone, was tested in vitro against 587 clinical isolates. The MICs for 90% of isolates of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae were 0.20, 1.56, and 0.39 microgram/ml, respectively. The MICs for 90% of isolates of Pseudomonas aeruginosa and Serratia marcescens were both 3.12 micrograms/ml. WIN 49375 was minimally active against gram-positive cocci. Its in vitro activity suggests that it may be useful for the treatment of gram-negative bacillary infections.